- Home
- CEV vs EPIX Comparison
CEV vs EPIX Comparison
Compare CEV & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CEV
- EPIX
- Stock Information
- Founded
- CEV 1999
- EPIX 2009
- Country
- CEV United States
- EPIX Canada
- Employees
- CEV N/A
- EPIX N/A
- Industry
- CEV Finance/Investors Services
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- CEV Finance
- EPIX Health Care
- Exchange
- CEV Nasdaq
- EPIX Nasdaq
- Market Cap
- CEV 71.8M
- EPIX 76.8M
- IPO Year
- CEV N/A
- EPIX N/A
- Fundamental
- Price
- CEV $10.27
- EPIX $1.72
- Analyst Decision
- CEV
- EPIX Hold
- Analyst Count
- CEV 0
- EPIX 3
- Target Price
- CEV N/A
- EPIX $2.00
- AVG Volume (30 Days)
- CEV 19.6K
- EPIX 252.4K
- Earning Date
- CEV 01-01-0001
- EPIX 02-11-2025
- Dividend Yield
- CEV 4.23%
- EPIX N/A
- EPS Growth
- CEV N/A
- EPIX N/A
- EPS
- CEV 0.36
- EPIX N/A
- Revenue
- CEV N/A
- EPIX N/A
- Revenue This Year
- CEV N/A
- EPIX N/A
- Revenue Next Year
- CEV N/A
- EPIX N/A
- P/E Ratio
- CEV $29.36
- EPIX N/A
- Revenue Growth
- CEV N/A
- EPIX N/A
- 52 Week Low
- CEV $8.83
- EPIX $1.40
- 52 Week High
- CEV $10.91
- EPIX $9.92
- Technical
- Relative Strength Index (RSI)
- CEV 59.52
- EPIX 47.93
- Support Level
- CEV $10.09
- EPIX $1.69
- Resistance Level
- CEV $10.30
- EPIX $1.83
- Average True Range (ATR)
- CEV 0.05
- EPIX 0.07
- MACD
- CEV 0.01
- EPIX 0.01
- Stochastic Oscillator
- CEV 87.50
- EPIX 57.69
About CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.